Phase I/II clinical trial of ALT-801, a T-cell receptor/IL-2 fusion protein, plus gemcitabine and cisplatin in urothelial cancer.
Mayer N. Fishman
Honoraria - Altor BioScience
Research Funding - Altor BioScience
Julio Hadjenberg
Research Funding - Altor BioScience
Timothy Kuzel
Research Funding - Altor BioScience
Amit Mahipal
No relevant relationships to disclose
Charles Joel Rosser
Research Funding - Altor BioScience
Danny Landau
Research Funding - Altor BioScience
Shilpa Gupta
No relevant relationships to disclose
Daniel A. Vaena
Research Funding - Altor BioScience; Altor BioScience
Sanjiv S Agarwala
Research Funding - Altor BioScience
John Francis Mahoney
Research Funding - Altor BioScience
Jean H. Hoffman-Censits
Research Funding - Altor BioScience; Altor BioScience
Wayne Harris
Research Funding - Altor BioScience
Mohammed M. Milhem
Research Funding - Altor BioScience
Jeffrey S. Weber
Consultant or Advisory Role - Altor BioScience
Peter Rhode
Employment or Leadership Position - Altor BioScience; Altor BioScience
Stock Ownership - Altor BioScience; Altor BioScience
Research Funding - Altor BioScience; Altor BioScience
Tessa Schutt
Employment or Leadership Position - Altor BioScience; Altor BioScience
Stock Ownership - Altor BioScience
Research Funding - Altor BioScience; Altor BioScience
Liza Hernandez
Employment or Leadership Position - Altor BioScience; Altor BioScience
Stock Ownership - Altor BioScience
Research Funding - Altor BioScience; Altor BioScience
Bee-Yau Huang
Employment or Leadership Position - Altor BioScience; Altor BioScience
Stock Ownership - Altor BioScience
Research Funding - Altor BioScience; Altor BioScience
Hing C. Wong
Employment or Leadership Position - Altor BioScience
Stock Ownership - Altor BioScience
Research Funding - Altor BioScience